Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom - 21/06/19
, Shaloo Gupta, MSc b, Abhijit Gadkari, PhD c, Puneet Mahajan, PhD d, Joel M. Gelfand, MD eAbstract |
Background |
The disease burden of atopic dermatitis (AD) in European populations is not well known.
Objective |
To establish the disease burden in European adult patients with AD.
Methods |
Data were from the 2016 National Health and Wellness Survey conducted in France, Germany, Italy, Spain, and the United Kingdom. Bivariate analyses were conducted on outcomes between controls without AD matched to patients with self-reported AD (both n = 1860).
Results |
Patients with AD and a subset of patients with inadequately controlled AD (IC-AD) versus controls without AD, respectively, reported significantly higher (P < .001) 36-Item Short Form Health Survey Physical and Mental Component Summaries (PCS, MCS), and anxiety (31.9% and 51.7% vs 14.4%), depression (25.8% and 36.2% vs 12.9%), and sleep disorder (22.7% and 39.7% vs 12.6%) prevalences. Patients with IC-AD versus controls without AD reported significantly greater (P < .001) overall work (57.1% vs 23.7%) and activity impairment (51.7% vs 26.5%). In addition, 21.6% of patients with AD and 37.9% of patients with IC-AD reported ≥1 emergency department visit in the previous 6 months versus 16.5% of controls without AD, and 93.1% of patients with AD versus 84.2% of those without AD had ≥1 clinician visit (both P < .001). Of these, patients with IC-AD showed greater burden on most outcomes than patients with controlled AD.
Limitations |
Low response rate, possible selection bias due to survey technology availability, and patient-reported data susceptible to recall bias.
Conclusion |
Patients with AD reported significant burden on health, health-related quality of life, productivity, activities, and health care.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, disease burden, Europe
Abbreviations used : AD, C-AD, DLQI, ED, HCRU, HRQoL, IC-AD, MCS, NHWS, PCS, SF-36v2, US
Plan
| Funding sources: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc, with involvement in publication decisions. |
|
| Conflicts of interest: L.E. and P.M. are employees of and stockholders in Sanofi. S.G. is an associate of Kantar Health, which received research funding from Sanofi/Regeneron Pharmaceuticals, Inc, for the current study. A.G. is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. J.M.G. is an employee of the University of Pennsylvania Perelman School of Medicine, which has received research funding from Sanofi/Regeneron Pharmaceuticals, Inc. In the previous 12 months, J.M.G. served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Regeneron Pharmaceuticals, Inc, Valeant, and Pfizer Inc, receiving honoraria, and received research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Eli Lilly, Janssen, Novartis, Regeneron, Sanofi, and Pfizer Inc, and has received payment for continuing medical education work related to psoriasis. He is also a copatent holder of Resiquimod for the treatment of cutaneous T-cell lymphoma. |
|
| Reprints not available from the authors. |
Vol 81 - N° 1
P. 187-195 - juillet 2019 Retour au numéro
Article précédent
- Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients
- Maxim Polansky, Rachel Eisenstadt, Taryn DeGrazia, Xiwen Zhao, Yuan Liu, Ron Feldman
- A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis
- Danka Svecova, Martin W. Lubell, Florence Casset-Semanaz, Harald Mackenzie, Roland Grenningloh, James G. Krueger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?